Novel Pulmonary Delivery of Antiviral Drugs for Treating COVID-19 in Patients with Parkinson’s Disease

2021 ◽  
Vol 18 ◽  
Author(s):  
Nazrul Islam ◽  
Shafiqur Rahman
Keyword(s):  
Public Health ◽  
Drug Delivery ◽  
Antiviral Drug ◽  
Pulmonary Delivery ◽  
Therapeutic Benefit ◽  
Antiviral Drugs ◽  
Effective Strategy ◽  
Delivery Methods ◽  
Significant Burden ◽  
Delivery Technology

: The COVID-19 pandemic has caused a significant burden on public health worldwide. Currently, there are limited medications for the treatment of COVID-19 in patients with Parkinson’s disorder (PD). Several antiviral drugs and other pharmacotherapies have shown promise and are used by various delivery methods. Among the antiviral drugs, amantadine alone was reported to provide therapeutic benefit against COVID-19 in patients with PD. Here we propose novel strategies for pulmonary drug delivery technology of antiviral drug amantadine. As such pulmonary delivery of this drug or combination with the additional antiviral drugs could be a more effective strategy for the treatment of COVID-19-related complications in patients with PD. Furthermore, the important benefits and limitations of this novel delivery technology will be discussed.

Possible benefits of reformulating antiviral drugs with nanoemulsion system in the treatment of novel coronavirus infection

Coronaviruses ◽  
2020 ◽  
Vol 01 ◽  
Author(s):  
Manish Kumar ◽  
Chandra Prakash Jain
Keyword(s):  
Drug Delivery ◽  
Drug Therapy ◽  
Pulmonary Surfactant ◽  
Antiviral Drug ◽  
Treatment Strategies ◽  
Drug Dosage ◽  
Antiviral Drugs ◽  
Antiviral Action ◽  
Coronavirus Infection ◽  
Novel Coronavirus

Background: An outbreak of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection or COVID 19, causing serious threats to all around the world. Until an effective and safe vaccine for novel coronavirus is developed by scientists, current drug therapy should by optimize for the control and treatment of COVID 19. Objective: In this manuscript, we are presenting a perspective on possible benefits of reformulating antiviral drug dosage form with nanoemulsion system against novel coronavirus infection. Methods: Literature review has been done on COVID 19, treatment strategies, novel drug delivery systems and role of pulmonary surfactant on lungs protection. Results: Nanoemulsion system and its components have certain biophysical properties which could increase the efficacy of drug therapy. Antiviral drugs, delivered through a nanoemulsion system containing P-gp inhibitor (surfactant and cosolvent), can inhibit the cellular resistance to drugs and would potentiate the antiviral action of drugs. Pulmonary surfactant (PS) assisted antiviral drug delivery by nanoemulsion system could be another effective approach for the treatment of COVID 19. Use of functional excipients like pulmonary surfactant (PS) and surfactant proteins (SPs), in the formulation of the antiviral drug-loaded nanoemulsion system can improve the treatment of coronavirus infection. Conclusion: In our opinion for synergizing antiviral action, lipid and protein portion of PS and their commercial analogs should be explored by pharmaceutical scientists to use them as a functional excipient in the formulation of antiviral drugloaded nanoemulsion system.

scholarly journals Microfabricated Engineered Particle Systems for Respiratory Drug Delivery and Other Pharmaceutical Applications

2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
Andres Garcia ◽  
Peter Mack ◽  
Stuart Williams ◽  
Catherine Fromen ◽  
Tammy Shen ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Small Molecule ◽  
Pulmonary Delivery ◽  
Respiratory Drug Delivery ◽  
Dry Powder ◽  
Powder Characteristics ◽  
Powder Particles ◽  
Microelectronics Industry ◽  
Delivery Technology ◽  
Microfabrication Techniques

Particle Replication in Non-Wetting Templates (PRINT®) is a platform particle drug delivery technology that coopts the precision and nanoscale spatial resolution inherently afforded by lithographic techniques derived from the microelectronics industry to produce precisely engineered particles. We describe the utility of PRINT technology as a strategy for formulation and delivery of small molecule and biologic therapeutics, highlighting previous studies where particle size, shape, and chemistry have been used to enhance systemic particle distribution properties. In addition, we introduce the application of PRINT technology towards respiratory drug delivery, a particular interest due to the pharmaceutical need for increased control over dry powder characteristics to improve drug delivery and therapeutic indices. To this end, we have produced dry powder particles with micro- and nanoscale geometric features and composed of small molecule and protein therapeutics. Aerosols generated from these particles show attractive properties for efficient pulmonary delivery and differential respiratory deposition characteristics based on particle geometry. This work highlights the advantages of adopting proven microfabrication techniques in achieving unprecedented control over particle geometric design for drug delivery.

scholarly journals A Review on Nanoparticles Drug Delivery System

2021 ◽  
Vol 11 (4) ◽  
pp. 101-104
Author(s):  
Kranti Pawar ◽  
Ramanlal Kachave ◽  
Madhuri Kanawade ◽  
Vinayak Zagre
Keyword(s):  
Drug Delivery ◽  
Targeted Delivery ◽  
Polymeric Micelles ◽  
Pulmonary Delivery ◽  
Potential Method ◽  
Medication Administration ◽  
Nasal Drug Delivery ◽  
Delivery Methods ◽  
Medication Delivery ◽  
Parenteral Drug

The method or process of delivering a pharmaceutical ingredient to create a therapeutic effect in people or animals is referred to as drug delivery. Nasal and pulmonary routes of medication administration are becoming increasingly important in the treatment of human illnesses. These methods, especially for peptide and protein therapies, provide potential alternatives to parenteral drug administration. Several medication delivery methods have been developed for this purpose and are being tested for nasal and pulmonary delivery. Chitosan, Alginate, vanilline oxalate, zinc oxalate, cellulose, polymeric micelles, Gliadin, and phospholipid are examples of these. Multidrug resistance, a key issue in chemotherapy, can be reversed with these nanoparticles. Surgery, chemotherapy, immunotherapy, and radiation are all well-established treatments used in cancer treatment. A nanoparticle has emerged as a potential method for the targeted delivery of medicines used to treat certain illnesses. Keywords: Nasal Drug Delivery, Pulmonary Drug Delivery, Nanoparticles

Recent Advances in Novasome Formulation Technology

2014 ◽  
Vol 7 (2) ◽  
pp. 2407-2411
Author(s):  
J M Shah ◽  
N.H Shah ◽  
Hadiya P D
Keyword(s):  
Drug Delivery ◽  
Effective Means ◽  
Entrapment Efficiency ◽  
Bilayer Membrane ◽  
Water Soluble ◽  
Delivery Methods ◽  
Liposomal Drug ◽  
Pharmaceutical Technology ◽  
Insoluble Drugs ◽  
Novel Drug

Pharmaceutical technology has developed various newer modes of novel drug delivery aspects. Modifications in the previously existing drug delivery methods have led to various newly innovated technologies serving as a safe and effective means of improvement over the existing ones. Novasome technology is one of the new innovations of liposomes which have solved many of the problems related to liposomal drug delivery system. It offers a seven bilayer membrane which has the ability to incorporate both water soluble and insoluble drugs. It has an excellent entrapment efficiency which provides better medication. Formulation of novasomes is achieved in a high shear device. Due to its numerous advantages, novasomes have been used extensively in various fields like cosmetics, chemical, personal care, foods, pharmaceuticals and agrochemicals.

Transferrin-Conjugated Nanocarriers as Active-Targeted Drug Delivery Platforms for Cancer Therapy

2017 ◽  
Vol 23 (3) ◽  
pp. 454-466 ◽  
Author(s):  
Daniele R. Nogueira-Librelotto ◽  
Cristiane F. Codevilla ◽  
Ammad Farooqi ◽  
Clarice M. B. Rolim
Keyword(s):  
Drug Delivery ◽  
Cancer Therapy ◽  
Tumor Cells ◽  
Therapeutic Benefit ◽  
Active Targeting ◽  
Future Research ◽  
Passive Targeting ◽  
The Right ◽  
Review Current ◽  
Target Effects

A lot of effort has been devoted to achieving active targeting for cancer therapy in order to reach the right cells. Hence, increasingly it is being realized that active-targeted nanocarriers notably reduce off-target effects, mainly because of targeted localization in tumors and active cellular uptake. In this context, by taking advantage of the overexpression of transferrin receptors on the surface of tumor cells, transferrin-conjugated nanodevices have been designed, in hope that the biomarker grafting would help to maximize the therapeutic benefit and to minimize the side effects. Notably, active targeting nanoparticles have shown improved therapeutic performances in different tumor models as compared to their passive targeting counterparts. In this review, current development of nano-based devices conjugated with transferrin for active tumor-targeting drug delivery are highlighted and discussed. The main objective of this review is to provide a summary of the vast types of nanomaterials that have been used to deliver different chemotherapeutics into tumor cells, and to ultimately evaluate the progression on the strategies for cancer therapy in view of the future research.

Repurposed Antiviral Drugs for the Treatment of COVID-19: Syntheses, Mechanism of Infection and Clinical Trials

2020 ◽  
Vol 21 ◽  
Author(s):  
Subha Sankar Paul ◽  
Goutam Biswas
Keyword(s):  
Public Health ◽  
Clinical Trial ◽  
Clinical Trials ◽  
Small Molecule ◽  
Mode Of Action ◽  
Antiviral Drugs ◽  
Public Health Emergency ◽  
Advanced Stage ◽  
Clinical Trial Results

: COVID-19 is a public health emergency of international concern. Although, considerable knowledge has been acquired with time about the viral mechanism of infection and mode of replication, yet no specific drugs or vaccines have been discovered against SARS-CoV-2, till date. There are few small molecule antiviral drugs like Remdesivir and Favipiravir which have shown promising results in different advanced stage of clinical trials. Chloroquinine, Hydroxychloroquine, and Lopinavir-Ritonavir combination, although initially was hypothesized to be effective against SARS-CoV-2, are now discontinued from the solidarity clinical trials. This review provides a brief description of their chemical syntheses along with their mode of action and clinical trial results available in Google and different peer reviewed journals till 24th October 2020.

Recent Advances in Gastric Floating Drug Delivery Technology: A Review

2013 ◽  
Vol 10 (3) ◽  
pp. 286-298 ◽  
Author(s):  
Rakesh Pahwa ◽  
Seema Bisht ◽  
Vipin Kumar ◽  
Kanchan Kohli
Keyword(s):  
Drug Delivery ◽  
Recent Advances ◽  
Floating Drug Delivery ◽  
Delivery Technology

Nanoparticle-based drug delivery systems with platinum drugs for overcoming cancer drug resistance

2021 ◽  
Author(s):  
Peng Xie ◽  
Yushu Wang ◽  
Dengshuai Wei ◽  
Lingpu Zhang ◽  
Bin Zhang ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Resistance ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Cancer Drug ◽  
Platinum Drugs ◽  
Effective Strategy ◽  
Platinum Drug ◽  
Cancer Drug Resistance ◽  
Platinum Drug Resistance

The mechanisms of chemoresistance and nanoparticle-based drug delivery systems for platinum drugs were detailed summarized in this review. The current combination therapy provided an effective strategy to overcome the platinum drug resistance.

scholarly journals Flexible Polymeric Nanosized Micelle for Ophthalmic Drug Delivery: Research Progress in Recent Three Years

2021 ◽  
Author(s):  
Zhiguo Li ◽  
Mingting Liu ◽  
Lingjie Ke ◽  
Li-Juan Wang ◽  
Caisheng Wu ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Complex Structure ◽  
Research Progress ◽  
Ophthalmic Drug Delivery ◽  
Ophthalmic Drug ◽  
Delivery Technology

The eye is a complex structure with a variety of anatomical barriers and clearance mechanisms, so the provision of safe and effective ophthalmic drug delivery technology is a major challenge....

Serum microRNA-122 Levels in Egyptian Patients with Chronic Hepatitis C virus Genotype 4 Infection before and after treatment with Direct Acting Antiviral Drugs

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Essam Mohammad Bayoumy Helal ◽  
Moataz Mohammad Sayed ◽  
Tari Magdy Aziz George ◽  
Christina Alfons Anwar ◽  
Sara Hassan Agwa ◽  
...  
Keyword(s):  
Public Health ◽  
Viral Hepatitis ◽  
Large Scale ◽  
Antiviral Drug ◽  
University Hospital ◽  
Health Concern ◽  
Virus Genotype ◽  
Genotype 4 ◽  
Hcv Therapy ◽  
Therapeutic Value

Abstract Background Viral hepatitis was estimated to be the 7th leading cause of mortality globally. About half of this mortality is attributed to HCV, a primary cause for liver fibrosis, cirrhosis and cancer. The recent development of highly efficacious oral DAAs provides opportunities for reducing HCV disease burden and its onward transmission, with the potential for eliminating this blood-borne virus as a public health concern. WHO has recently formulated the ‘Global Health Sector Strategy on Viral Hepatitis, 2016– 2021 with service coverage targets to eliminate HCV as a public health threat by 2030. Objective To asses the possible relation of miRNA 122 to HCC development after HCV therapy with direct antiviral drug. Patients and Methods Previous studies suspect that HCV therapy by DAAS may increase risk of HCC so the aim of our study is to evaluate miR-122level at end of HCV treatment by DAAS and compare the results with miR-122level in HCC patients. The study was performed as a case control study in Ain Shams University hospital and Suez Canal authority hospital (Outpatient Clinic), at Ismailia Egypt in the period between Augusts to October 2018. Results These results revealed an effect of treatment by DAAs in HCV infected patients leading to miRNA 122 reduction and this may be related to hepatocarcinogenesis. However, further studies on a large patients number are needed to clarify this point and determine the diagnostic and possible therapeutic value of miRNA 122 in HCV infected patients. Conclusion Baseline MiR-122 level at cutoff value ≤0.26 was significantly lower in HCC patients than chronic HCV patients and normal controls, with a sensitivity of 80%, a specificity of 70%. MiR-122 was significantly reduced at end of HCV therapy with DAAs and became similar to values in HCC patients. Whether this observed reduction is mechanistically related to hepatocarcinogenesis is still a possibility, to be clarified in furtur large scale studies. The reduction of MiR-122 at the end of HCV therapy with DAAs was significantly observed in (F3,F4) patients than those with early fibrosis stages(F1,F2).This again gives a possible explanation of HCC development in HCV patients with advanced fibrosis(cirrhosis)and raises the question about the diagnostic and therapeutic value of miRNA 122 (and possibly other miRNAs)in the management strategy of HCV infected patients.

Sign in / Sign up

Export Citation Format

Share Document